We are all familiar with the phrase, “Save the Best for Last,” and as we finish up our special GLP-1 Series, we have done exactly that. This week we have the completion of an interview that our publisher, Steve Freed, did with Dr. David D’Alessio, Associate Professor of Medicine, Division …

In a special bonus issue of our GLP-1 Special Series, we presented this excellent and informative interview with Dr. Alan Moses, Global CMO, Novo Nordisk. Dr. Moses gave us his take on the latest in GLP-1 technologies as well as a peek at Novo’s efforts in developing world-class therapies in …

Diabetes In Control Publisher Steve Freed interviewed Dr. David D’Alessio, Associate Professor of Medicine, Division of Endocrinology, University of Cincinnati, and the Albert Vontz chair in Diabetes Research. Dr. D’Alessio helps us understand some of the newest research on GLP-1’s, how he uses these therapies in his own practice and …

Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath Mr. VR was referred to the endocrinology department of a major hospital to ‘get his diabetes fixed up’ after he presented to the emergency department. Mr. VR is a 69-year-old man …

Topics covered include the clinical effects of GLP-1 agonists and DPP-4 inhibitors stemming from incretin action, and the role of glucagon in glucose intolerance and effects of GLP-1 based drugs on plasma glucagon…. Link to download (.ppt format): GLP-1 Effectiveness, Mechanisms of Action and Potential, Part 1 of 4 Other sets …

If you think that the U.S. House and Senate are on two totally different paths on spending, taxes and deficit management, they don’t even come close to the vastly different paths that the FDA and the European Union are taking. It appears that the EU has decided that diabetes is …

  By Sheri Colberg, PhD   Most of the focus of diabetes management and prevention is on losing weight. However, I think that the emphasis on weight loss alone is misguided for several reasons, and we need to find a way to focus on beneficial changes in body composition instead …

Over the past two months we have provided you with a special GLP-1 newsletter. During this time we have seen that the science behind this class of drugs known as GLP-1- Analogs is solid and the results are positive. Many of you asked for more information on how the native …

Bydureon Coming Soon See this week’s Item #1, Lilly Resubmits Bydureon to FDA, for more information.

Welchol Suspension Works in Fruit Juices, Diet Soda Daiichi Sankyo has received U.S. regulatory approval for a new formulation of its diabetes drug Welchol. This new suspension can be mixed with fruit juice and diet soft drinks  The drug lowers blood sugar and LDL cholesterol in patients with type 2 …